{"entity":{"id":"micvotabart-pelidotin","kind":"drug","name":"Micvotabart pelidotin","aka":["PYX-201","MICVO"],"tldr":"Micvotabart pelidotin is an experimental antibody-drug conjugate from Pyxis Oncology, in phase 1 trials for advanced solid tumours, with a focus on recurrent or metastatic head and neck squamous cell carcinoma.","summary":"Micvotabart pelidotin (PYX-201) is an antibody-drug conjugate (auristatin payload) from Pyxis Oncology. Targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tissue around tumour cells and releases an auristatin payload there. Pyxis focuses it on recurrent or metastatic head and neck squamous cell carcinoma; it is in a phase 1 study alone (NCT05720117) and a phase 1/2 study in combination (NCT06795412), both in advanced solid tumours. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"Pyxis Oncology clinical programmes","url":"https://pyxisoncology.com/clinical-programs/"},{"label":"ClinicalTrials.gov NCT06795412","url":"https://clinicaltrials.gov/study/NCT06795412"},{"label":"ClinicalTrials.gov NCT05720117","url":"https://clinicaltrials.gov/study/NCT05720117"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["fn1"],"drugs":[],"companies":["pyxis-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06795412","nct05720117"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"PYX-201","modality":"Antibody-drug conjugate (auristatin payload)","mechanism":"Targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tissue around tumour cells and releases an auristatin payload there.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/micvotabart-pelidotin/","neighbours":{"target":[{"id":"fn1","kind":"target","name":"FN1","route":"/targets/fn1/"}],"company":[{"id":"pyxis-oncology","kind":"company","name":"Pyxis Oncology","route":"/companies/pyxis-oncology/"}],"trial":[{"id":"nct05720117","kind":"trial","name":"A Study of PYX-201 in Advanced Solid Tumors","route":"/trials/nct05720117/"},{"id":"nct06795412","kind":"trial","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct06795412/"}]}}